🇺🇸 FDA
Pipeline program

DEXAMETHASONE , DARATUMUMAB, DARZALEX 1800 mg solution for injection, LENALIDOMIDE

Phase 3 small_molecule active

Quick answer

DEXAMETHASONE , DARATUMUMAB, DARZALEX 1800 mg solution for injection, LENALIDOMIDE for Onco-hematology is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Onco-hematology
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials